At Liquidia Corp (LQDA), Chief Accounting Officer Dana Boyle sold 5,892 common shares on October 12, 2026, at $28.48 per share under a Rule 10b5-1 plan adopted December 15, 2023; the shares covered taxes associated with settling RSUs and PSUs. On October 9, 2026, 3,178 performance stock units converted one-for-one into common shares. The reported post-conversion performance stock unit position was 28,609.
Liquidia Corp (LQDA) Chief Business Officer Jason Adair converted 3,906 restricted stock units into 3,906 common shares on October 9, 2026, and converted performance stock units into 2,474 and 3,868 common shares that day. On October 12, 2026, he sold 7,301 common shares at $28.48 per share to cover taxes associated with RSU and PSU settlements. The sale was made under a Rule 10b5-1 plan adopted December 15, 2023.
Liquidia Corp director Stephen M. Bloch reported that Canaan VIII L.P. sold 235,477 shares of common stock on October 5, 2026, at a weighted average price of $27.1262 per share; sales ranged from $26.745 to $27.59. Canaan LP reported zero shares afterward. Bloch separately held 104,570 shares directly, including 32,976 received in a distribution. The reported amount reflects a reduction for shares previously distributed by Canaan LP for no consideration, and Bloch did not participate in the investment decision. No Rule 10b5-1 plan is reported.
Liquidia Corporation reported that a Delaware federal court found claims 1 and 14 of U.S. Patent No. 11,826,327 valid and infringed by Liquidia in litigation concerning YUTREPIA; the other asserted claims were found invalid.
The court directed the parties to submit a form of judgment specifying their proposed remedies within one week. Liquidia said the remedy remains uncertain, and potential remedies could range from removing PH-ILD from YUTREPIA’s label to a broader restriction on availability; United Therapeutics requested injunctive relief restricting availability. Chief Executive Officer Roger Jeffs said Liquidia disagrees with the decision, is prepared to pursue available appellate options, and intends to submit an FDA supplement to remove PH-ILD from the label.
Liquidia Corp director Raman Singh reported multiple option exercises and related share sales. On September 11 and September 14, 2026, he exercised options covering a total of 17,492 shares of common stock at exercise prices of $8.63 and $9.3055 per share and sold the resulting shares in market transactions.
Sales totaled 17,492 shares at per-share prices of $66.16 and a volume weighted average price of $68.6181, with the latter reflecting trades between $68.60 and $68.70. No Rule 10b5-1 trading plan is reported, and the filing notes 5,882 unvested restricted stock units included in his overall equity awards.
Liquidia Corp (LQDA) received a notice that director Ramandeep Singh intends to sell shares of its common stock under Rule 144. The notice covers 8,468 shares to be sold on September 14, 2026, following a stock option exercise, with Morgan Stanley Smith Barney LLC as the broker. The filing also reports a prior sale of 9,024 shares on September 11, 2026.
Liquidia Corp (LQDA) director Ramandeep Singh filed a Rule 144 notice covering the potential sale of common stock. The notice lists 9,024 shares of common stock held at Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $619,209.73, and indicates the shares are tied to a stock option exercise for cash, with a proposed sale date of September 11, 2026 on NASDAQ.
Liquidia Corp (LQDA) reported that Chief Human Resource Officer Sarah Krepp sold 274 shares of common stock on September 1, 2026 at a volume weighted average price of $67.76 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan and was made to cover taxes on settling Restricted Stock Units. After the sale, she directly held 117,308 shares, including multiple grants of unvested RSUs and shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corporation (LQDA) reports that the U.S. Food and Drug Administration has granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a serious, high-mortality autoimmune disease with no FDA-approved therapy specifically for SSc-RP.
Liquidia plans to start the RE-WARM Phase 2a study in October 2026 in about 75 adults with SSc experiencing symptomatic Raynaud's attacks, across up to 30 U.S. sites, with primary completion targeted for February 2027. YUTREPIA is already approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease but not for SSc-RP.
Liquidia Corp (LQDA) insider Jason Adair, Chief Business Officer, exercised stock options for a total of 31,799 shares of common stock at exercise prices of $9.31 and $14.20 per share and on the same date sold 73,631 shares at a volume-weighted average price of $69.0908 per share. The sales, including those of option exercise shares, were effected pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2025. Adair continues to hold common stock and multiple tranches of unvested RSUs in Liquidia.